Nautilus Biotechnology remains too speculative and faces eventual Nasdaq delisting if it cannot hold above $1. A price floor just under $1 after its collapse looks technically supportive, and there are early signs of commercial interest, but it is still a wild card. x.com 

Biotech tools stocks such as Charles River and Illumina are in a narrative-driven mania while their fundamentals haven't really moved. Charles River is ripping after reaffirming guidance for negative revenue growth this year. Illumina hasn't grown in five years, yet trades at over 50x earnings and 35x EV/EBITDA, with merely fine margins. Five straight years of easier comparisons are being sold as a coiled spring. x.com  x.com  x.com 

Voyager's single-molecule approach could make Nautilus the most asymmetric proteomics bet if it works. Quarterly grant revenue of about $0.2m against over $10m consumed leaves it reliant on capital; a $125m ATM risks dilution. Repeated slips make the mid-2027 launch less likely to hold; independent customer validation and a sales channel are absent. Adoption could justify billions; delay or low-price issuance could send shares below $2 again. Tempus AI remains the preferred larger holding. x.com 

New Era Energy & Digital's roughly $450M market cap makes little sense against about $1M of revenue. x.com 

Nautilus Biotechnology could become extraordinarily important to oncology by reading intact proteoform states across cancer's redundant signaling pathways. Before-and-after tumor measurements could train AI to find the smallest effective, tumor-specific drug combination beyond mutation-guided care. It has not shown it can map every clinically relevant cancer proteoform or prescribe curative combinations. AI-biology companies must buy Nautilus now or face painfully compressed margins. x.com  x.com 

Nautilus Biotechnology is entering commercialization and could become the Illumina of proteomics. Its early access program signed Baylor College of Medicine as first customer for an NIH-funded cancer project. Its tau assay with the Buck Institute quantifies up to 768 full-length tau proteoforms, beyond traditional methods, which could draw pharma demand or M&A interest as Alzheimer's drug work heats up. Its $143 million cash lasts past 2028 at $14-16 million quarterly burn, avoiding dilution. … Show more

Zeta Global and Nautilus Biotechnology are two versions of the same idea, seeing deeper than anyone else: Zeta into the customer, Nautilus into the molecule. Both are aligned with something everyone wants, better information, and moved first to build the platforms that deliver it. Neither guarantees success, but both greatly raise the odds, which creates the asymmetry. Zeta is much further along in its zero-to-one journey. x.com